Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Kaposi Sarcoma

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

Kaposi Sarcoma

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Derived from NCI topic(s): Kaposi Sarcoma. Strongest NCIt resolution: exact. Entity-level scope; stage, biomarker and treatment line are not yet part of this definition.
      source wording
      Source null
      5 more-specific settings
      DOXIL: Kaposi's Sarcoma after prior therapy →Pomalyst: Kaposi sarcoma after prior therapy →Pomalyst: Kaposi sarcoma after prior therapy →localized Kaposi Sarcoma →advanced Kaposi Sarcoma →

      Study evidence for this setting

      6 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT01154452 · Registry condition search · Scope: narrower

      Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma

      3 outcome links · 4 safety-group records · 0 quality-of-life measures

      →

      NCT01296815 · Registry condition search · Scope: narrower

      Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity

      2 outcome links · 2 safety-group records · 0 quality-of-life measures

      →

      NCT01495598 · Source cited / selected · Scope: narrower

      Pomalidomide for Kaposi Sarcoma in People With or Without HIV

      6 outcome links · 1 safety-group records · 3 quality-of-life measures

      →

      NCT02595866 · Registry condition search · Scope: narrower

      Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

      6 outcome links · 5 safety-group records · 0 quality-of-life measures

      →

      NCT04514484 · Registry condition search · Scope: narrower

      Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV

      6 outcome links · 1 safety-group records · 0 quality-of-life measures

      →

      NCT05510908 · Registry condition search · Scope: narrower

      Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

      6 outcome links · 3 safety-group records · 2 quality-of-life measures

      →

      Indication-specific source history

      Dated source events, not confirmation of current approval for every use of a drug.

      1995-11-17 · Doxil (doxorubicin hydrochloride) · accelerated approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-kaposi-sarcoma
      event id
      fda-adbafcec05e20f1a
      event date
      1995-11-17
      event kind
      accelerated-approval
      drug or regimen
      Doxil (doxorubicin hydrochloride)
      source indication text
      Kaposi's sarcoma in AIDS patients with disease progression on prior combination chemotherapy or who are intolerant to such therapy
      match phrase
      kaposi's sarcoma
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-2c728fdb471249a514e9
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      2008-06-10 · Doxil (doxorubicin hydrochloride) · traditional approval
      release id
      clinical-indications-draft-1
      disease state id
      ds-kaposi-sarcoma
      event id
      fda-e545287c18f0b224
      event date
      2008-06-10
      event kind
      traditional-approval
      drug or regimen
      Doxil (doxorubicin hydrochloride)
      source indication text
      Kaposi's sarcoma in AIDS patients with disease progression on prior combination chemotherapy or who are intolerant to such therapy
      match phrase
      kaposi's sarcoma
      match status
      candidate
      status category
      verified_clinical_benefit
      has date discrepancy
      0
      source collection
      fda-status-row
      source key
      fda-aa-2c728fdb471249a514e9
      source url
      https://www.fda.gov/drugs/resources-information-approved-drugs/verified-clinical-benefit-cancer-accelerated-approvals
      curation status
      draft
      reviewed by
      Source null
      reviewed at
      Source null
      created at
      2026-09-10T00:00:00Z
      Original event source →
      Source relationships and population-mapping limitations
      bindings
      1. release id
        clinical-indications-draft-1
        disease state id
        ds-kaposi-sarcoma
        binding id
        ncit-C9087
        source collection
        ncit-concept
        source key
        C9087
        source excerpt
        Source null
        match status
        exact
        match note
        Source null
        recorded at
        2026-09-10T00:00:00Z
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice